Trial · NCT07903623
QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia
NCT07903623, Phase 2, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia. Trials, record NCT07903623. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903623
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia
- NCT number
- NCT07903623
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 15 participants, estimated
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Conditions
- Primary Plasma Cell Leukemia
- Interventions
- QLS4131, Isatuximab
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Minimal residual disease (MRD) negative rate | After 9 cycles (each cycle is 28 days) | |
| Secondary | Incidence and severity of adverse events (AEs) | From the first dose of QLS4131 through 30 days after the last dose of QLS4131, up to approximately 18 months | |
| Secondary | Duration of MRD negativity | From the date of first documented MRD negativity until disease progression, death, or end of follow-up, whichever occurs first, assessed up to approximately 36 months. | |
| Secondary | Overall Response Rate (ORR) | Up to 18 treatment cycles, each cycle is 28 days | |
| Secondary | Complete Response Rate (CRR) | Up to 18 treatment cycles, each cycle is 28 days | |
| Secondary | Progression-free survival (PFS) | From the first dose of study treatment until the date of first documented disease progression or death from any cause, whichever occurs first, up to approximately 36 months. | |
| Secondary | Overall survival (OS) | From the first dose of study treatment until death from any cause, up to approximately 36 months. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903623
GET https://conductscience.org/api/trials/v1/NCT07903623/registered